On September 18, the General Administration of Market Regulation website showed that the case of a new joint venture between Shiyao Group Co., Ltd. and AstraZeneca Mainland Co., Ltd. entered the publicity period. The publicity period is from September 18, 2026 to September 27, 2026. CSPC Group Co., Ltd. and AstraZeneca Mainland Co., Ltd. signed a transaction agreement on August 3. According to the transaction agreement, CSPC and AstraZeneca Mainland plan to establish a joint venture. The joint venture will be engaged in biopharmaceutical contract production organization services. After the deal, CSPC and AstraZeneca Mainland will hold 51% and 49% of the joint venture's shares, respectively, and jointly control the joint venture.

On September 18, the General Administration of Market Regulation website showed that the case of a new joint venture between Shiyao Group Co., Ltd. and AstraZeneca Mainland Co., Ltd. entered the publicity period. The publicity period is from September 18, 2026 to September 27, 2026. CSPC Group Co., Ltd. and AstraZeneca Mainland Co., Ltd. signed a transaction agreement on August 3. According to the transaction agreement, CSPC and AstraZeneca Mainland plan to establish a joint venture. The joint venture will be engaged in biopharmaceutical contract production organization services. After the deal, CSPC and AstraZeneca Mainland will hold 51% and 49% of the joint venture's shares, respectively, and jointly control the joint venture.